Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nkarta, Inc.NKTX · Entity 6346 | Chief Legal Officer | January 15, 2025 | January 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nkarta, Inc.
Report date January 15, 2025 · Filed January 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,735 |
Reported balance
After 2025-01-15 transaction · row 1
1 source rowRow 1 · 2025-01-15 · Sale · Disposed 9,584 · Balance 146,735 F1: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OncoMed Pharmaceuticals Inc
Report date April 23, 2019 · Filed April 23, 2019
Section 16 reporting ended · disclosed 2019-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-23 transaction · row 1
1 source rowRow 1 · 2019-04-23 · Other · Disposed 39,488 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2025 Filed Jan 17, 2025 17:35 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 9,584 | $2.20 | $21,084.80 |
DisclosureSEC source: 0000950170-25-006823 · ownership.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,735 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000950170-25-002832 · ownership.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 16:06 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 52,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002832 · ownership.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,319 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2026. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 16:22 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 3,396 | $8.00 | $27,168.00 |
DisclosureSEC source: 0000950170-24-084588 · ownership.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,819 F1 · kind: The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on March 28, 2024. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 17:02 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 727 | $5.60 | $4,071.20 |
DisclosureSEC source: 0000950170-24-075728 · ownership.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,215 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.58 to $5.60. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:38 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 4,554 | $8.74 | $39,801.96 |
DisclosureSEC source: 0000950170-24-005425 · ownership.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,942 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.74 to $8.96. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 16:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-24-001158 · doc4.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2034-01-03 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2024. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 16:45 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 56,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001158 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,496 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 16:23 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 701 | $4.85 | $3,399.85 |
DisclosureSEC source: 0001209191-23-039057 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,496 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 19:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,103 | $5.49 | $6,055.47 |
DisclosureSEC source: 0001209191-23-003852 · doc4.xml · nonDerivative · entry 2 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,197 F2 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 19:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001209191-23-003852 · doc4.xml · derivative · entry 3 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-12 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2023. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 19:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003852 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,300 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2024. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 19:08 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 50,500 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001209191-22-038528 · doc4.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2032-06-16 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 17, 2022. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 19:08 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038528 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,800 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:51 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-003755 · doc4.xml · derivative · entry 3 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-01-13 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2022. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:51 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 76,800 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-003755 · doc4.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,800 Underlying: Common Stock · 76,800 shares Expires 2032-01-13 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2022. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 16:51 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 12,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003755 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 13:23 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $54.89 | $0.00 |
DisclosureSEC source: 0000899243-21-001463 · doc4.xml · derivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2031-01-07 F1 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 8, 2021. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 18:29 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $31.11 | $0.00 |
DisclosureSEC source: 0000899243-20-029553 · doc4.xml · derivative · entry 1 Hager Alicia J. · CIK 0001553354 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-10-25 F1 · derivative.exercise_date: The option is scheduled to vest and become exercisable as to 25% of the shares subject to the grant on October 26, 2021. The remaining portion of the option is scheduled to vest and become exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following October 26, 2021. Read SEC document |
| April 23, 2019 Filed Apr 23, 2019 16:16 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | OtherCommon Stock | 39,488 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010990 · doc4.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2 · price: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 18:56 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 1,156 | $2.02 | $2,335.12 |
DisclosureSEC source: 0001567619-18-004055 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,754 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.0100 to $2.1719, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 30,001 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 09, 2018 Filed Oct 10, 2018 19:38 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 1,686 | $2.13 | $3,589.16 |
DisclosureSEC source: 0001567619-18-003955 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,910 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.1005 to $2.1289, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 33,126 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 24, 2018 Filed Apr 26, 2018 18:11 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 4,051 | $2.68 | $10,847.77 |
DisclosureSEC source: 0001140361-18-019831 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,596 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $2.613 to $2.682771, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 37,709 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 19:06 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0001140361-18-001272 · doc1.xml · derivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 18:33 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 1,202 | $4.24 | $5,098.64 |
DisclosureSEC source: 0001140361-17-038564 · doc1.xml · nonDerivative · entry 2 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,647 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 47,709 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 18:33 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 46 | $4.26 | $195.98 |
DisclosureSEC source: 0001140361-17-038564 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,849 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock units ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 47,709 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Read SEC document |
| October 07, 2017 Filed Oct 10, 2017 19:27 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 36,666 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001140361-17-038097 · doc1.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,666 Underlying: Common Stock · 36,666 shares Expires 2027-10-06 F3 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 07, 2017 Filed Oct 10, 2017 19:27 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 18,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038097 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,895 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 50,834 RSUs. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:09 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001140361-17-016763 · doc1.xml · derivative · entry 2 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-04-22 F3 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:09 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-016763 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,561 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 32,500 RSUs. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:39 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 4,284 | $9.06 | $38,805.33 |
DisclosureSEC source: 0001140361-17-015046 · doc1.xml · nonDerivative · entry 2 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,561 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:39 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 32 | $8.87 | $283.98 |
DisclosureSEC source: 0001140361-17-015046 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,845 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:57 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,652 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001140361-17-012630 · doc1.xml · derivative · entry 3 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,652 shares Expires 2018-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 15, 2016. F3 · derivative.exercise_date: The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:57 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 6,652 | $10.00 | $66,520.00 |
DisclosureSEC source: 0001140361-17-012630 · doc1.xml · nonDerivative · entry 2 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,877 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 15, 2016. F2 · balance_after: Includes 23,750 restricted stock units. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:57 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionCommon Stock | 6,652 | $3.42 | $22,749.84 |
DisclosureSEC source: 0001140361-17-012630 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,529 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 15, 2016. F2 · balance_after: Includes 23,750 restricted stock units. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:10 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001140361-17-000854 · doc1.xml · derivative · entry 1 Hager Alicia J. · CIK 0001553354 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 09, 2016 Filed Oct 11, 2016 21:41 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-082537 · doc1.xml · nonDerivative · entry 1 Hager Alicia J. · CIK 0001553354 · VP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,877 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 23,750 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.